RAD51C
RAD51C (DNA repair protein RAD51 homolog 3) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer, Breast cancer, Gastric & gastro-oesophageal junction cancer and 2 more.
Overview
Essential for the homologous recombination (HR) pathway of DNA repair. Involved in the homologous recombination repair (HRR) pathway of double-stranded DNA breaks arising during DNA replication or induced by DNA-damaging agents. Part of the RAD51 paralog protein complexes BCDX2 and CX3 which act at different stages of the BRCA1-BRCA2-dependent HR pathway.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Olaparib. Open Targets scores its association with cancer at 0.87 (direct and indirect evidence; datatypes genetic literature 0.86, affected pathway 0.81, literature 0.97, genetic association 0.88, somatic mutation 0.96, animal model 0.25).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · RAD51C (DNA repair protein RAD51 homolog 3) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer, Breast cancer, Gastric & gastro-oesophageal junction cancer and 2 more.
- 1 · What it is
RAD51C (DNA repair protein RAD51 homolog 3) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer, Breast cancer, Gastric & gastro-oesophageal junction cancer and 2 more.
- 2 · What goes wrong in cancer
Essential for the homologous recombination (HR) pathway of DNA repair. Involved in the homologous recombination repair (HRR) pathway of double-stranded DNA breaks arising during DNA replication or induced by DNA-damaging agents.
- 3 · How drugs use it
No product in this corpus aims at RAD51C yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:9820 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O43502 (protein name, function text, keywords and locations (REST API)); CIViC gene RAD51C (1 evidence items, 0 assertions, 1 variants; diseases: Castration-resistant Prostate Carcinoma (GraphQL API, CC0)); Open Targets ENSG00000108384 (association with cancer (MONDO_0004992) 0.87; per-cancer scores at or above 0.5: gastric cancer 0.61, ovarian cancer 0.83, melanoma 0.50, breast cancer 0.82 (GraphQL API, CC0))
Biology
Essential for the homologous recombination (HR) pathway of DNA repair. Involved in the homologous recombination repair (HRR) pathway of double-stranded DNA breaks arising during DNA replication or induced by DNA-damaging agents. Part of the RAD51 paralog protein complexes BCDX2 and CX3 which act at different stages of the BRCA1-BRCA2-dependent HR pathway. Upon DNA damage, BCDX2 seems to act downstream of BRCA2 recruitment and upstream of RAD51 recruitment; CX3 seems to act downstream of RAD51 recruitment; both complexes bind predominantly to the intersection of the four duplex arms of the Holliday junction (HJ) and to junction of replication forks. The BCDX2 complex was originally reported to bind single-stranded DNA, single-stranded gaps in duplex DNA and specifically to nicks in duplex DNA. The BCDX2 subcomplex RAD51B:RAD51C exhibits single-stranded DNA-dependent ATPase activity suggesting an involvement in early stages of the HR pathway. Location: Nucleus; Cytoplasm; Cytoplasm, perinuclear region; Mitochondrion (UniProt). Locus 17q22 (HGNC).
- Ovarian cancer: Open Targets association 0.83 with ovarian cancer (MONDO_0008170)
- Breast cancer: Open Targets association 0.82 with breast cancer (MONDO_0007254)
- Gastric & gastro-oesophageal junction cancer: Open Targets association 0.61 with gastric cancer (MONDO_0001056)
- Prostate cancer: CIViC evidence names this disease
- Melanoma: Open Targets association 0.50 with melanoma (MONDO_0005105)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 1 clinical evidence items on its variants; UniProt keyword "DNA repair". Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"RAD51C" OR ABSTRACT:"RAD51C" OR TITLE:"RAD51 paralog C" OR ABSTRACT:"RAD51 paralog C" OR TITLE:"DNA repair protein RAD51 homolog 3" OR ABSTRACT:"DNA repair protein RAD51 homolog 3" OR TITLE:"RAD51L2" OR ABSTRACT:"RAD51L2" OR TITLE:"FANCO" OR ABSTRACT:"FANCO") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RAD51C, not a curated reading list.